Ibrx earnings date
Webb12 mars 2024 · View the latest ImmunityBio Inc. (IBRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Webb30 mars 2024 · IBRX Next Earnings Date: 4/10/2024 7:00 AM (Projected earnings date) Earnings Period: FY 2024: Earnings Estimate:-0.270/share: Revenue Estimate: 0.02M: …
Ibrx earnings date
Did you know?
WebbIBRX Earnings Date Earnings announcement* for IBRX:. Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings... Earnings Per Share. Yearly … WebbImmunityBio (IBRX) - NASDAQ: Next Earnings Date: Estimated on March 1, 2024 EVR: 1.3 Avg Daily Volume: 1,826,377 Market Cap: 1.23B Sector: None Short Interest: 28.77 Live Interactive Chart: Days to Next Earnings: 7 Days : Implied Move Monthly: 26.69% Expires on: March 17 ...
http://nextearningsdate.com/ibrx.html WebbNASDAQ: IBRX ImmunityBio (IBRX) Earnings Date & Reports 506 Followers Portfolio Earnings Data Report Date May 10, 2024 Not Confirmed Period Ending 2024 (Q1) …
WebbCompare the earnings yield of Immunitybio IBRX and Replimune Group REPL. Get comparison charts for value investors! ... Dividend Contenders Minimum 3% Yield Minimum 4% Yield Minimum 5% Yield Low Payout Ratio Undervalued Monthly Payers Upcoming Ex-Dates Upcoming Payers. Value Screeners. WebbIBRX Earnings Forecast The previous quarter’s earnings for IBRX were -$0.27. IBRX Sales Forecast The previous quarter’s earnings for IBRX were $73.00K. No data currently available IBRX Analyst Recommendation Trends IBRX has not received any ratings in the last 3 months. Detailed List of Analyst Forecasts Analyst Profile Expert Firm Price Target
Webb4 mars 2024 · ImmunityBio (NASDAQ:IBRX) Full Year 2024 Results Key Financial Results. Net loss: US$416.6m (loss widened by 20% from FY 2024). US$1.04 loss per share (further deteriorated from US$0.89 loss in FY 2024). NasdaqGS:IBRX Earnings and Revenue Growth March 4th 2024. All figures shown in the chart above are for the …
Webb21 mars 2024 · This is an estimated date of earnings release. ... Research for IBRX. More Info. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports. cisplatin fluorouracilWebb12 mars 2024 · ImmunityBio Inc. IBRX (U.S.: Nasdaq) REAL TIME 12:00 PM EDT 04/05/23 $1.6694USD -0.0106 -0.63% Volume 2,119,885 65 Day Avg Vol 3,332,438 1 … diamond\u0027s 0sWebbImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N … diamond\\u0027s 0tWebb27 maj 2024 · Breaking News: IBRX latest news. - The Fly. ... Smith and Wesson options imply 9.0% move in share price post-earnings 06/23/22 ... The FDA just accepted the BLA for lead asset Anktiva for BCG-unresponsive NMIBC and set a PDUFA date in May of next year, noted Shi, ... diamond\\u0027s 1Webb28 mars 2024 · The latest earnings per stock, revenues and financial reports for Immunitybio Inc (IBRX). Earnings Insights View advanced earnings insights to get an in … cisplatin fkWebb11 apr. 2024 · Companies. The trading price of ImmunityBio Inc. (NASDAQ:IBRX) closed lower on Monday, April 10, closing at $1.58, -3.66% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $1.52 and $1.67. In examining the 52-week price action we see that the stock hit a 52 … diamond\\u0027s 0yWebbOn Thursday 03/23/2024 the closing price of the NantKwest Inc Registered Shs share was $1.46 on NAS. Compared to the opening price on Thursday 03/23/2024 on NAS of … cisplatin for bladder cancer